FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite
Otsuka plans a slow, measured launch of Abilify MyCite, developed with Proteus Health. The product includes an ingested sensor that sends a signal to a wearable patch and an app that tracks ingestion, activity and mood to potentially improve management of psychiatric care.
You may also be interested in...
During a panel at the 2022 BioFuture conference, panelists talked about how digital technology can provide data about drugs and devices on the market or in clinical trials.
The latest drug approval and development news from our US FDA Performance Tracker.
Original new drugs and biologics recently approved by US FDA.